MedTrace Logo

Open Label Pharmacokinetic-Pharmacogenetic Study on Polymorphisms in the Organic Cation Transporter OCT1

NCT02054299 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2016-05-12

No results posted yet for this study

Summary

The purpose of this study is to determine the effect of the organic cation transporter OCT1 polymorphisms on the pharmacokinetics of several drugs in order to explain efficacy and adverse effects.

Conditions

  • Drug Metabolism
  • Membrane Transport

Interventions

DRUG

Drug application Amitriptyline

Amitriptyline: 25 mg, single oral application

DRUG

Drug application Desvenlafaxine

Desvenlafaxine: 50 mg, single oral application

DRUG

Drug application Sumatriptan

Sumatriptan: 50 mg, single oral application

DRUG

Drug application Proguanil

Proguanil: 200mg, single oral application

DRUG

Drug application Fenoterol

Fenoterol: 180 mcg, single intravenous application

DRUG

Drug application Thiamine

Thiamine: 200mg, single oral application

Sponsors & Collaborators

  • University Medical Center Goettingen

    lead OTHER

Principal Investigators

  • Juergen Brockmoeller, Prof. · University Medical Center Goettingen

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2016-02-29
Completion
2016-02-29

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02054299 on ClinicalTrials.gov